智通财经APP获悉,7月21,知名基金经理谢治宇旗下公募产品披露2025年二季报。以投资范围涵盖港股的兴全合宜为例,二季度该基金A份额收益率为4.26%,跑赢业绩比较基准(同期增长率1.91%)。该基金的港股仓位由42.69%提升至45.01%,信达生物(01801)、诺诚健华(09969)两只热门港股创新药标的新进入该基金的前十大重仓股,持有市值分别为8.00亿元、5.33亿元。此外,蓝思科技(...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.